There is a need for novel effective and safe therapies for metastatic breast cancer based on targeting tumor-specific molecular markers of cancer. Human aspartyl (asparaginyl) b-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins and is overexpressed in a variety of cancers, including breast cancer. A fully human monoclonal antibody (mAb) PAN-622 has been developed to HAAH. In this study, they describe the development of PAN-622 mAb as an agent for imaging and radioimmunotherapy of metastatic breast cancer. PAN-622 was conjugated to several ligands such as DOTA, CHXA †, and DTPA to enable subsequent radiolabeling and its immunoreactivity was evaluated by an HAAHspecific enzyme-linked immunosorbent assay and binding to the HAAH-positive cells. As a result, DTPA-PAN-622 was chosen to investigate biodistribution in healthy CD-1 female mice and 4T1 mammary tumor-bearing BALB/c mice. The In-DTPA-pan622 mAb concentrated in the primary tumors and to some degree in lung metastases as shown by SPECT/CT and Cherenkov imaging. A pilot therapy study with 213 Bi-DTPA-PAN-622 demonstrated a significant effect on the primary tumor. The authors concluded that human mAb PAN-622 to HAAH is a promising reagent for development of imaging and possible therapeutic agents for the treatment of metastatic breast cancer.
Introduction
H uman aspartyl (asparaginyl) b-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins. Overexpression of this enzyme has been detected in a variety of cancers, including breast cancer. [1] [2] [3] [4] [5] In contrast, the expression of HAAH in normal tissue is low and the protein is generally localized only to internal compartments (e.g., endoplasmic reticulum). It has been demonstrated that on cellular transformation, HAAH is overexpressed and translocated to the tumor cell surface, rendering it a specific surface antigen for tumor cells.
Although significant progress has been made in recent decades in treatment of metastatic breast cancer, 6 it still remains a formidable threat occupying third place in the list of cancers killing the highest number of American women and men (American Cancer Society data). Thus, there is a need for novel effective and safe therapies for metastatic breast cancer based on targeting tumor-specific molecular markers of cancer. 7 Radioimmunotherapy (RIT) involves selective targeting of radionuclides to cancer-associated cell surface antigens using monoclonal antibodies (mAbs). RIT permits the delivery of a high dose of therapeutic radiation to cancer cells, while minimizing the exposure of normal cells. Although this approach has been investigated for several decades, the cumulative advances in cancer biology, antibody engineering, and radiochemistry in the past decade have markedly enhanced the ability of RIT to produce durable remissions of multiple cancer types. cells. 3 Furthermore, the antibody has been shown to internalize into tumor cells and serve as a vehicle for the delivery of cytotoxic moieties. 3 In this study, the authors describe the development of the PAN-622 mAb as an agent for imaging and RIT of metastatic breast cancer.
Materials and Methods

Conjugation of PAN-622 to various ligands to enable radiolabeling
PAN-622 and its conjugates were produced by Goodwin Biotechnology (Plantation, FL). To enable radiolabeling of PAN-622 with diagnostic and therapeutic radionuclides, it was conjugated to NHS-DOTA and maleimide-DOTA, bifunctional CHXA †, and maleimide-DTPA. Two conjugation procedures were performed as follows:
(1) Random Conjugation: The purified PAN-622 antibody (5 mg/mL) was concentrated and diafiltered into the conjugation buffer (50 mM sodium carbonate, 150 mM sodium chloride, 5 mM EDTA, pH 8.6) using Amicon Ultra 50 kDa MWCO filters. Bi generator provided by the European Commission, Karlsruhe, Germany. 9 For radiolabeling of the conjugates with 111 In, 100 lg of each conjugate in ammonium acetate buffer, pH 5.5, was placed in a 0.5 mL low protein binding Eppendorf tube. Two microliters of 111 In solution (200 lCi) in 0.15 M ammonium acetate buffer, pH 5.5, was added to each tube, thus making the specific activity of radiolabeled protein 2 lCi/lg. The samples were incubated for 30 minutes at 37°C in an orbital thermomixer at 1000 rpm. At the end of the incubation period, the reaction was quenched with the addition of 3 lL 0.05 M EDTA and the radiolabeling yields were assessed as below. For radiolabeling with 213 Bi, the 225 Ac/ 213 Bi generator was eluted with 500 lL of 0.1 M HI. The eluant contained 150-1500 lCi 213 Bi. The pH of the eluant was adjusted to *5.0 by adding 80 lL of 2.5 M ammonium acetate buffer. This 213 Bi-containing solution was added to the tube with 100 lg DTPA-PAN-622 mAb, and the reaction mixture was incubated for 6 minutes at 37°C. At the end of the incubation period, the reaction was quenched by the addition of 3 lL 0.05 M EDTA, and the radiolabeling yield was assessed.
The radiolabeling yields were measured by instant thin layer chromatography. The 10 cm silica gel was spotted with 1 lL of radiolabeled antibody and developed in 0.15 M ammonium acetate buffer, pH 5.5. The strips were subsequently cut in half and counted in a c counter. The measurements were performed in triplicate. The radiolabeling yields were calculated as (R/(R+F)) · 100%, where R (radiolabeled) are the counts in the lower half of the strip where the radiolabeled antibody is localized and F (free) are the counts in the upper part of the strip where the free 111 In in the form of an EDTA complex is localized. The radiolabeled antibodies were subsequently analyzed by radio-high performance liquid chromatography (HPLC). A Waters HPLC system equipped with a Bioscan flow-through radiation detector was used. The size exclusion TSK3000XL column was eluted with PBS, pH 7.4, at 1 mL/min.
Cell binding and cell internalization studies
5 · 10 5 -2 · 10 6 4T1 mouse mammary cancer cells (CRL-2539; ATCC) were placed in 1 mL PBS in the Eppendorf tubes preblocked with 1% BSA to prevent binding of the radiolabeled antibody to the tubes. Each sample was prepared in triplicate. The counting the tubes in the c counter, spinning down the cell pellet, removing the supernatant, washing the pellet with 2 · 1 mL cold PBS, and counting the cell pellets in the c counter. To ascertain the specificity of 111 In-DTPA-PAN-622 binding to HAAH on 4T1 cells, the authors used the 111 In-labeled isotope matching control mAb 2556, which is a fully human mAb to HIV-1 gp41 glycoprotein. 10 As an additional control, they used 4T1 cells preincubated for 1 hour with 10 lg/mL PAN-622.
The internalization of 111 In-DTPA-PAN-622 into the 4T1 cells was investigated using the methodology described in Ref. 11 Briefly, the 4T1 cells were incubated with 111 In-DTPA-PAN-622 at 4°C for 1 hour to obtain surface labeling with minimal internalization. Aliquots of 10 6 cells were then placed into separate tubes and supernatants were separated from cells. Immediately after separation, cells underwent acid wash and acid-resistant radioactivity was determined by counting cell pellets after centrifugation. This procedure was repeated at various times after transferring cell aliquots to an incubator at 37°C. Acid-resistant fraction was determined by dividing activity in cell pellet after acid wash by total activity on cell after 1 hour of incubation at 4°C.
Biodistribution of 111 In-PAN-622 in healthy mice
All animal experiments were performed according to the protocol approved by the Institute for Animal Studies at the In-DTPA-PAN-622 antibody (0.020 mg and 50 lCi per mouse). Mice were euthanized at 1, 12, 24, 48, and 96 hours subsequent to dosing (n = 5 mice per time point). Tissue samples (brain, muscle, bone, heart, lung, liver, spleen, kidneys, stomach, large intestine, blood, and urine) were collected from each mouse, weighed, and the accumulated activity per tissue counted in a c counter. 
Results
Attachment of DTPA to PAN-622 via maleimide conjugation enabled radiolabeling and preserved PAN-622 immunoreactivity
The authors initially investigated the suitability of random attachment of the bifunctional CHXA †-DTPA chelator to the PAN-622 antibody for subsequent radiolabeling with 111 In. The nonreducing sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) showed some attachment of CHXA †-DTPA to PAN-622 (Supplementary Fig. S1A ; Supplementary Data are available online at www.liebertpub.com/cbr). Conjugation of PAN-622 with a 2-to 20-fold molar excess of CHXA"-DTPA resulted in increasing levels of radiolabeling from 11.7% to 61.1%, however, at a 50-fold molar excess, radiolabeling yield dropped precipitously to 3.0% (Table 1). Unfortunately, increased levels of conjugation with CHXA" also resulted in a loss of binding capacity to both recombinant HAAH protein and to tumor cells (Fig. 1A,  B) . Next, both the site-specific conjugation via DOTA-MAL and random conjugation via NHS-DOTA of the macrocyclic chelator DOTA to PAN-622 were attempted. No radiolabeling of resulting conjugates with 111 In was observed, pointing to possible incompatibility of a large macrocycle molecule with PAN-622 (Table 1 ). In the final attempt, site-specific conjugation of DTPA-MAL chelator to the PAN-622 mAb was done. DTPA-MAL chelator was attached to PAN-622 using 8, 15, and 30 minutes of reaction times. The resulting conjugates after 15-or 30-minute reactions were labeled with 111 In with a 93% efficiency (Table 2 ). These conjugates showed structural intactness by size exclusion HPLC (Fig. 2) and nonreducing SDS-PAGE (Supplementary Fig. S1B ) and preserved their immunoreactivity toward HAAH as per ELISA and cell binding (Fig. 1C, D) . In all subsequent in vivo experiments, the 15-minute maleimide DTPA-PAN-622 conjugate was used. 
Binding of 111
In-DTPA-PAN-622 to 4T1 cells was HAAH specific and resulted in its internalization
The binding of 111 In-DTPA-PAN-622 to 4T1 cells is shown in Figure 3A In-DTPA-PAN-622 into the cells (Fig. 3B) , which was completed by 8 hours. No internalization of the control mAb 111 In-DTPA-2556 into the cells was observed (Fig. 3B) .
Biodistribution of
111 In-DTPA-PAN-622 in healthy mice demonstrated its overall stability and fast clearance from major organs Figure 4 shows the results of the biodistribution of 111 In-DTPA-PAN-622 in healthy female CD-1 mice. The radiolabeled conjugate cleared rapidly from the circulation with less than 1% ID/gram remaining in the blood at 96 hours postinjection. The clearance from the blood-rich organs such as the heart and lungs followed the same trend. The processing and excretion of the In-DTPA-PAN-622 conjugate followed the hepatobiliary route, which is typical for the conjugates labeled with a trivalent residualizing radiometal such as 111 In. This in vivo stability of 111 In-DTPA-PAN-622 provided the impetus for the follow-up experiments in mammary tumor-bearing mice. In-DTPA-PAN-622 in 4T1 tumor-bearing female BALB/c mice confirmed the fast clearance of the radiolabeled conjugate from the circulation and demonstrated its specific uptake in 4T1 primary tumors and elevated uptake in the lung metastases (Fig. 5) . The tumor and lung uptake of 111 In-DTPA-PAN-622 was also observed on Cherenkov luminescence images (Fig. 6) . To the best of knowledge, these are the first reported in vivo images of Cherenkov luminescence from 111 In, which besides c rays also emits Auger electrons. It is important to note here that Cherenkov luminescence in vivo is not a quantitative technique as the intensity of emitted light depends on the depth in the body and can only complement conventional biodistribution. In-DTPA-PAN-622 in the peritoneum of the untreated mice which was practically absent in the 213 Bi-DTPA-PAN-622-treated mice (Fig. 7) . This can be explained by the micrometastatic spread of the tumor cells in the peritoneum. In treated mice, the majority of activity was concentrated in the liver where the antibody is metabolized.
There was some diffuse uptake of 111 In-DTPA-PAN-622 in the lungs of the untreated mice, and no visible uptake in the lungs of 213 Bi-DTPA-PAN-622-treated mice. The pathological investigation revealed that the weight of the primary tumors was significantly ( p = 0.04) less in 213 Bi-DTPA-PAN-622-treated mice than in untreated (Fig. 8A) . The number of metastases in the lungs of both groups was practically the same ( p = 0.08) (Fig. 8B) . REVSKAYA ET AL.
Discussion
In this study, the authors investigated the utility of the radiolabeled fully human antibody, PAN-622, which targets HAAH for the in vivo imaging and therapy of metastatic breast cancer. HAAH has emerged as a promising biomarker of cancer cells. [1] [2] [3] [4] [5] HAAH is an oncofetal antigen that modulates NOTCH signaling pathways during embryogenesis. [13] [14] [15] [16] In the adult mammal, HAAH expression is generally low and is localized to the intracellular compartments. Several studies have demonstrated that it is not significantly expressed on the surface of normal human tissues. 5, 17 The protein is most highly expressed in the trophoblastic cells, where it is thought to play a role in uterine implantation. 13, 16, 18 PAN-622 has been previously developed as a fully human anti-HAAH antibody for use in immunotherapy of cancer without the radiolabel. 3 There was some uptake in the heads of all mice visible on Cherenkov and SPECT images but not confirmed by the biodistribution data. It has been demonstrated that HAAH is expressed in primitive neuroectodermal tumors but not in normal brain. 19 The authors would posit that as the 4T1 is a highly invasive and metastatic tumor, which is well established to metastasize to the brain 20, 21 -the uptake in the head might be due to the metastases in the skull. It is unclear whether this observation is significant or not and thus warrants further investigation. The number of metastases in the lungs of both groups was practically the same; it might be possible that some of those Bi-DTPA-PAN-622-treated group do not have any cells left expressing HAAH and for that reason there was no lung uptake on the microSPECT/CT images. Also, the 1-week lag between the last imaging session and opening of the mice might have contributed to the emergence of additional lung metastases.
Several radioimmunoimaging and RIT preclinical studies targeting other surface antigens such as HER-2 or EGFR in breast cancer with b-, a-, or Auger electron-emitting radionuclides are currently ongoing. [22] [23] [24] For the pilot therapy study in 4T1 tumor-bearing mice, the authors have selected an a-emitter
213
Bi. The use of targeted therapy with aparticle emitters in oncology is burgeoning worldwide. This is driven by the advantages of a-emitters over b-emitters, including very specific targeting of the diseased cells due to the a-particles' short 50-80 lm tissue range, and increased killing efficiency due to high linear energy transfer. This results in a controlled therapeutic modality with minimal normal tissue effects. 25 RIT with a-emitters does not depend on the oxygenation status of the tumor or its resistance to chemotherapy and external beam radiation therapy, as recently demonstrated by 213 Bi-labeled peptide-induced remission in patients with neuroendocrine tumors refractory to b-radiation. 26 In particular, 213 Bi-labeled mAbs have been used in multiple clinical trials for several oncologic indications and have demonstrated efficacy without major sideeffects. 27, 28 Likewise, the multiple administrations of 213 Bi-DTPA-PAN-622 in this study was well tolerated with treated animals showing no changes in their body conditioning scores. In contrast to this complete absence of toxicity, the researchers who used 225 Ac-labeled trastuzumab had to resort to intraductal administration of the radiolabeled antibody because of the high systemic toxicity of 225 Ac-trastuzumab. 22 Li et al. also utilized trastuzumab, which they labeled with Auger electron emitter 111 In to kill human breast cancer cells, 23 however, their results are so far only preliminary in vitro data, and it remains to be seen if 111 In will show promise in treating experimental breast cancer in vivo. The study, where the engineered immunoconjugates labeled with more traditional radionuclide 177 Lu and targeting both HER2 and EGFR on the surface of breast cancer xenografts in mice were used, 24 demonstrated comparable efficacy and lack of toxicity observed in this work.
In conclusion, these results demonstrated that radiolabeled human mAb PAN-622 to HAAH is a promising reagent for imaging and possible therapy of metastatic breast cancer. Further experiments in a mouse model of breast cancer with parallel use of two cell lines-one expressing HAAH and the other one not expressing HAAH, are currently being planned. Since HAAH is overexpressed in other cancers the use of radiolabeled PAN-622 will be explored in other cancers as well.
